Trial Profile
A Retrospective Study to Compare the 3-Year Antiviral Efficacy of Nevirapine and Efavirenz in Combination With D4t and 3tc in 2NN Patients and of Trizivir Versus Trizivir Plus Nevirapine in CHARM Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Nevirapine (Primary) ; Efavirenz; Lamivudine; Lamivudine/zidovudine/abacavir; Stavudine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms 2NN; CHARM
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 04 Jul 2013 New source identified and integrated: European Clinical Trials Database record.
- 28 Oct 2006 New trial record.